Zhengzhou Antu Bioengineering Co., Ltd. (hereinafter referred to as "Antu Biotechnology", stock code 603658) was founded in 1998. It focuses on the research, manufacturing, integration and services of in vitro diagnostic reagents and instruments. Its products cover immunity, microbial, biochemistry, and molecular , coagulation and other testing fields can provide medical laboratories with complete product solutions and overall services.

The company was listed on September 1, 2016. It is an in vitro diagnostic research and development and manufacturing enterprise listed on the main board of the Shanghai Stock Exchange. It has been approved as a National Enterprise Technology Center, a National Engineering Research Center for the Detection of New Major Infectious Diseases, and a National Immune Testing Automation Local joint engineering laboratories, etc. At present, the company has more than 600 product registration certificates and has obtained more than 1,000 patents. In 2021, the company's operating income was 3.766 billion yuan, a year-on-year increase of 26.45%. The Antu Bioinfravitation Diagnosis Industrial Park under construction is a key construction project in Henan Province. The construction land area is more than 251 mu and the construction area is more than 720,000 square meters. After completion, it will have a production capacity of 15 billion yuan, becoming the largest in vitro diagnosis in China. One of the industrial bases.

Antu Bio attaches great importance to product research and development and technological innovation, and has always regarded improving R&D and innovation capabilities as an important means to enhance the core competitiveness of the enterprise. The company attaches importance to R&D investment, and in the past three years, R&D investment has exceeded 10% of its operating income; it pays attention to team building, and technical R&D personnel account for about one-third of the company's total number; it is comparable to international advanced, and strictly manages R&D processes; it pays attention to R&D of core raw materials, The antigen and antibody self-sufficiency rate of immunodiagnostic reagent products reaches more than 77%. Antu Bio has become one of the companies in the industry with many registered documents and relatively complete product lines.

Antu Bio focuses on quality and pursues excellent manufacturing. In terms of reagent production, we will introduce automated production lines to improve product automation and flow operation level, and improve the level of refined management; in terms of instrument manufacturing, we will continue to increase the intensity of refined management and advocate the craftsman spirit of continuous excellence and continuous optimization; in terms of quality management, Passed GMP, ISO9001 and ISO13485 certifications, strictly manage quality assessment, and continuously promote quality improvement.

While Antu Bio focuses on independent innovation and excellent manufacturing, it also pays attention to global resource integration. Through the integration of R&D and innovation resources, and even industry advanced products, medical laboratories can provide richer products. Antu Bio takes "user first, create value" as its service concept, adheres to user-centeredness, continuously improves service standards and capabilities, and provides professional, timely and thoughtful technical services to users across the country. While providing product and technical services to users, it also provides quality control services and overall services to medical laboratories.

Antu Bio's marketing network covers the whole country, and customer-oriented academic and technical promotion activities are the marketing characteristics of Antu Bio. In terms of international marketing, the company's products have been sold to Europe, Asia, the Middle East, South America, Africa and other regions.